Literature DB >> 1348419

Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase.

A Garlind1, C J Fowler, I Alafuzoff, B Winblad, R F Cowburn.   

Abstract

The effects of a range of neurotransmitter agonists showing selectivity for receptor types inhibitorily coupled to adenylyl cyclase were compared in membrane preparations of hippocampus, frontal cortex and caudate nucleus/striatum from previously frozen post-mortem human and rat brain. Agonists were tested against basal and forskolin stimulated activities, forskolin being a potent activator of the catalytic sub-unit of the enzyme. Of those agonists tested, only somatostatin (100 microM) and neuropeptide Y (10 microM) gave consistent inhibitions of basal and forskolin stimulated enzyme activities in all three regions of both human and rat brain. Somatostatin-mediated inhibition of human brain adenylyl cyclase was reduced in the absence of GTP and in the presence of the guanine nucleotide partial agonist, guanosine 5'-O-thiodiposphate, consistent with a G-protein-linked receptor. No such GTP-dependence was found for the neuropeptide Y-mediated adenylyl cyclase inhibition. GTP-dependent somatostatin mediated inhibitions of human brain adenylyl cyclase activity were of highest magnitude in the thalamus, intermediate magnitude in the hippocampus and caudate nucleus and lowest magnitude in the frontal cortex. It is concluded that of a range of neurotransmitter receptor agonists tested, only somatostatin gives robust, GTP-dependent responses that are reproducible enough to be used with post-mortem tissue for the comparison of receptor function in human brain disorders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348419     DOI: 10.1007/bf01245013

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  33 in total

Review 1.  G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides.

Authors:  M Mousli; J L Bueb; C Bronner; B Rouot; Y Landry
Journal:  Trends Pharmacol Sci       Date:  1990-09       Impact factor: 14.819

2.  Characterization and regional distribution of adenylyl cyclase activity from human brain.

Authors:  R F Cowburn; A Garlind; C O'Neill; I Alafuzoff; B Winblad; C J Fowler
Journal:  Neurochem Int       Date:  1991       Impact factor: 3.921

3.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

4.  Differential effects of somatostatin on adenylate cyclase as functional correlate for different brain somatostatin receptor subpopulations.

Authors:  R Markstein; K A Stöckli; J C Reubi
Journal:  Neurosci Lett       Date:  1989-09-25       Impact factor: 3.046

5.  Somatostatin inhibition of adenylate cyclase activity in different brain areas.

Authors:  G Schettini; T Florio; O Meucci; E Landolfi; M Grimaldi; C Ventra; A Marino
Journal:  Brain Res       Date:  1989-07-17       Impact factor: 3.252

Review 6.  G protein involvement in receptor-effector coupling.

Authors:  P J Casey; A G Gilman
Journal:  J Biol Chem       Date:  1988-02-25       Impact factor: 5.157

7.  Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain.

Authors:  L Bergström; A Garlind; L Nilsson; I Alafuzoff; C J Fowler; B Winblad; R F Cowburn
Journal:  J Neurol Sci       Date:  1991-10       Impact factor: 3.181

8.  Somatostatin binding sites in human and monkey brain: localization and characterization.

Authors:  M F Beal; V T Tran; M F Mazurek; G Chattha; J B Martin
Journal:  J Neurochem       Date:  1986-02       Impact factor: 5.372

9.  Somatostatin receptors on cortical neurones and adenohypophysis: comparison between specific binding and adenylate cyclase inhibition.

Authors:  H Chneiweiss; P Bertrand; J Epelbaum; C Kordon; J Glowinski; J Premont; A Enjalbert
Journal:  Eur J Pharmacol       Date:  1987-06-19       Impact factor: 4.432

10.  Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists.

Authors:  M C Olianas; P Onali; N H Neff; E Costa
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.